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PRE-MODERN HISTORY OF
NEPHROLOGY
The kidneys have always been an object of
mystery and study from time immemo-
rial. Confucius considered them to be
one of the vital organs together with the
brain and heart. The Talmud suggests that
the kidneys are the seat of the soul, and
the liturgy of the high holidays describes
God as discerning what is in the heart
and kidneys of man. Various psalms and
passages from the Bible consider heart
and kidneys as symbol of somatic and
mental integrity (1). The Quran implies
important functions are resting within the
kidneys.
Richard Bright in 1827 was one of the
first clinicians to recognize the connec-
tion between renal damage and illness.
Although the label Bright’s disease is no
longer in use, it is a testament to the
astute acumen of this early 19th century
physician. Although he is thought to have
described a patient with post-infectious
glomerulonephritis, the small, shrunken
kidneys that are preserved in Guy’s Hos-
pital in London do not provide a clue
about the cause of the chronic disease. They
only illustrate the consequences of renal
scarring. Frederick Munk was the first to
describe minimal change nephrotic syn-
drome in the 1910s and coined the term
“lipoid nephrosis” for the disease called
“dropsy” based on the appearance of the
kidney tissue and urine. Although acute
kidney injury was not a new entity, it was
first diagnosed in living patients who suf-
fered crush injury and rhabdomyolysis-
induced kidney damage during the Lon-
don Blitz in World War II. However, until
the 1950s, there was very limited access to
the laboratory tests required to establish a
diagnosis of kidney disease, and there was
no impetus to change things because there
were no treatments for patients with renal
disorders.
ENTRY OF NEPHROLOGY INTO
MODERN MEDICINE
In 1954, Merrill and Murray performed
a kidney transplant between two identi-
cal twins and ushered nephrology into the
modern age (2). There had been a num-
ber of pioneering physicians and engineers
who were working on the development of
an artificial system to replace kidney func-
tion when the organ fails. However, Mer-
rill’s surgery represented a cure for CKD
by implanting a new functioning kidney
into a patient who had irreversible loss of
organ function. He was fortunate to have
access to an identical sibling and he could
avoid the hazards of organ rejection due
to immunologic disparity between the kid-
ney donor and recipient. Over the next
decade, the biology of tolerance and rejec-
tion was clarified by Peter Medawar lead-
ing to the discovery of immunosuppressive
drugs. This has been an area of gradual
improvement as safer and more effective
drugs are isolated and incorporated into
clinical practice. But it was Merrill who
pointed the way toward the feasibility of
correcting kidney failure and uremia. This
spurred research into the pathogenesis of
glomerular disease and clarification of the
role of the immune system. Laboratory
methods were introduced to enable rou-
tine measurement of BUN and creatinine
in clinical practice. With all these develop-
ments, nephrology emerged as a vibrant
subspecialty that combined exciting basic
science and a genuine possibility of treating
disease.
THE GOLDEN AGE OF NEPHROLOGY
In the 1960s, clinicians finally took advan-
tage of the work done by earlier investiga-
tors including Belding Scribner and began
to implement hemodialysis for patients
who had end stage kidney disease (ESKD).
Originally, the procedure was very ardu-
ous and dangerous because the device was
large and unwieldy and monitoring equip-
ment was virtually non-existent. Early on,
because dialysis was a scarce resource, com-
mittees were convened to decide which
patients should be given access to this lim-
ited resource. However, this led to pro-
found ethical dilemmas when these panels
were forced to make life or death decisions
regarding the care of individual patients.
In response to this untenable situation, a
law was passed by the US Congress in 1973
making any American citizen eligible for
Medicare coverage of dialysis treatment.
This represented the first time that an inter-
vention to replace organ function became
routinely available and that treatment for
a specific disease was designated as a right
or an economic entitlement. In response
to this law, dialysis programs were opened
throughout the US and the population of
patients being treated with hemodialysis
expanded dramatically. This number grew
even further with the development of peri-
toneal dialysis, an important option espe-
cially in patients with severe atherosclerotic
vascular disease or diabetes.
Nephrology practices and divisions
grew in size as they reaped the bene-
fits of the income generated by dialysis
units. Nephrology was an attractive field
for young physicians because it combined
high level, intellectually challenging clinical
work with sophisticated technical exper-
tize. It offered the hope of ameliorating
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disease in patients who previously had lan-
guished and died due to lack of treatment.
The excitement of dialysis and transplanta-
tion transformed the landscape of care for
individuals with ESKD. Finally, advances
in basic science such as perfusion of iso-
lated tubules made it possible to address
fundamental problems in renal physiol-
ogy. Many departments of medicine were
led by nephrologists and fellowship pro-
grams in nephrology successfully attracted
the best and the brightest in medicine and
pediatrics.
THE TECHNOLOGY DRIVEN AGE OF
NEPHROLOGY
However, there were problems looming
large on the horizon as dialysis became
the standard of care for ESKD. As the
procedure became safer and more com-
pact, it was applied to a wider range of
patients. The nephrologists and legislators
who passed the law making dialysis an enti-
tlement originally thought that the proce-
dure would be applied to a limited num-
ber of patients. However, over the next
three decades, dialysis was implemented
in an aging population with a wide range
of co-morbid conditions including dia-
betes, atherosclerotic cardiovascular dis-
ease, and early dementia. The cost of the
ESKD program grew exponentially pro-
voking a strong federal backlash to limit
spending on the dialysis. In addition, it
became increasingly clear that dialysis was
not curative and that the mortality asso-
ciated with ESKD was delayed but not
prevented. In part, the loss of enthusi-
asm for dialysis as a meaningful treatment
option was paralleled by a lack of ade-
quate federal support for kidney transplan-
tation in a growing dialysis population.
The gradual change in the patient pro-
file, treatment fatigue with dialysis to man-
age patients with ESKD, and the growing
perception that there were few meaning-
ful therapeutic options led to a notice-
able drop in enthusiasm among trainees
for careers in nephrology and disillusion
among established practitioners.
CHANGING PLACE OF NEPHROLOGY IN
MEDICAL CARE
While the incidence and prevalence of CKD
and ESKD continue to increase, the disci-
pline of nephrology faces serious challenges
in the coming years related to manpower
issues. In the US, trainees tend to no longer
view nephrology as the most attractive sub-
specialty. This may have a number of rea-
sons: (1) there has been an overall decrease
in the number of medical students opt-
ing for internal medicine due to perceived
concerns about lifestyle and compensa-
tion; (2) medical students and residents
are often no longer exposed to the breadth
of clinical nephrology or able to interact
with nephrologists one-on-one in either
preclinical or clinical settings; (3) there
are negative perceptions about the prac-
tice of nephrology that relate to the long
hours, relatively low compensation, focus
on a chronically ill and complicated pop-
ulation of patients, and uncertainty about
the future of the discipline. In this regard,
changes in the “business of nephrology”
in the past decades, with the centraliza-
tion of providers to an increasingly smaller
number of for-profit corporations and the
rules, regulations, and payment limitations
instituted by CMS, have led to a sense of
loss of physician autonomy; and (4) many
aspects of care that were historically under
the purview of nephrology are being ceded
to other disciplines, such as hypertension
to cardiologists and fluid and electrolyte
management to intensivists (3).
Although the number of US nephrol-
ogy trainees increased from 711 to 911
during the period 2002–2009, the num-
ber of applicants for fellowship has been
decreasing (hopefully), reaching a nadir
in 2013, when 24% of the available posi-
tions were unfilled through the National
Resident Matching Program. In addition,
the percentage of applicants who are US
medical graduates has steadily decreased,
with 64% international medical graduates
(IMGs) in 2013 (1, 4).
In addition to concerns about replen-
ishing the nephrology workforce, there are
also grave concerns about the future of
nephrology research. In general, in the US,
physician scientists are an increasingly rare
and endangered breed, and this is especially
true in nephrology, which has a strong and
proud history of physician scientist-based
discovery and scientific leadership. Fur-
thermore, there are fewer opportunities for
researchers in basic science departments to
be exposed to cutting edge kidney-related
research. In a recent analysis, Al-Awqati has
noted that the percentage of nephrology-
related papers published in The Journal
of Clinical Investigation peaked in the late
1970s and early 1980s and have since “been
declining over the past two decades in
almost a linear manner” (5).
As with the causes for the drop in inter-
est in a career in nephrology, there are
numerous possible reasons for decreased
interest in nephrology research. The debt
burden of many medical school graduates
is excessive, there is often a lack of exposure
during training to appropriate role models
or to kidney-related research, IMGs have
more limited funding sources available for
research training and must often opt for
practice rather than pursuing careers as
physician scientists, and there is general
uncertainty about future job security as a
researcher. The percentage of NIH dollars
committed to kidney-related research has
decreased steadily over the past decades.
In 2012, even prior to the sequestration of
2013, the success rate for ultimately obtain-
ing an RO1 for a kidney-related project
had decreased to 17%. In 2011, the average
age of a physician scientist receiving a first
RO1 was 45 years (4). Even more disturb-
ing, almost 30% of recipients of KO8 grants
do not even apply for an initial RO1 (4).
Finally, it must be admitted that research
in nephrology has not translated into the
same advances in medical care as have
been seen in many other areas of medical
research. From 1966 to 2002, there were
fewer RCTs in nephrology than any other
medical subspecialty (6), and this dispar-
ity has persisted for the succeeding decade.
Furthermore, between the years of 2002
and 2012, the FDA approved 37 urogenital-
related indications, some of which were to
previously marketed products with a new
nephrology-related indication. Of these 37
approvals, the majority were not even for
kidney-related drugs but addressed uro-
logic issues such as bladder conditions
or erectile dysfunction. For a comparison,
during the same time period, there were 85
approvals for oncology-related indications,
the vast majority of which represented new
drugs resulting from insights gained from
basic research (7).
CURRENT CHANGES IN NEPHROLOGY:
CLINICAL
With the arrival of the 21st century, it
has become clear that nephrology trails
most other medical subspecialties in the
performance and completion of adequately
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powered clinical trials (8, 9). There are
many factors that contribute to this issue,
a number of which revolve around the
nature of the patient population. These
include the low prevalence of kidney dis-
ease in the general population, a misper-
ception in lay community of the serious
health implications of CKD, and a lack
of novel agents with significant potential
to favorably impact the course of com-
mon renal disorders. In addition, there
has been a lack of standardization that
has hindered accurate delineation of the
epidemiology of common kidney prob-
lems. Finally, unlike oncology and special-
ized diseases such as adult respiratory dis-
tress syndrome, a stable renewable infra-
structure has not been established to fos-
ter the timely performance of multicenter
randomized clinical trials.
In recognition of these barriers to
clinical research, the nephrology commu-
nity has convened and begun to define
standards for key clinical problems. The
National Kidney Foundation has estab-
lished a classification scheme for the def-
inition of CKD that is divided into five
stages. This has fostered studies into the
incidence of CKD in different populations,
delineation of the cardiovascular risk asso-
ciated with CKD, and facilitated investi-
gations of early biomarkers of declining
kidney function. It is likely that this pro-
tocol will be revised to incorporate mea-
surements of proteinuria to better refine
diagnostic and prognostic implications of
disease staging. In addition, the acute kid-
ney injury network (AKIN) has drafted a
scheme based on changes in the serum
creatinine and urine output to catego-
rize patients with acute kidney injury into
stages with increasingly severe disease. The
classification protocols have been revised
and updated to reflect the unique features
of specific patient cohorts such as children
and neonates. But the overall effect has
been to create a sense of organization and
purpose to clinical research in AKI.
Glomerular diseases, in particular, are
an important and growing cause of patient
morbidity and mortality in all age groups.
There have been few therapeutic advances
in this area because of the rarity of the
disorders and the need for multicenter col-
laborative efforts. In the last 5 years, the
NIH-NIDDK has taken steps to rectify this
problem by establishing prospective cohort
studies of patients with incident (NEP-
TUNE) and prevalent (Cure GN) glomeru-
lar disease (10). These observational stud-
ies incorporate state-of-the-art technology
in genomics, proteomics, metabolomics,
and systems biology. It is anticipated
that these efforts will yield an improved
understanding of the pathophysiology of
glomerular disease, provide better tools
to define the nature and clinical course
of specific glomerulopathies, and guide
the design of therapeutics that target the
underlying cause of each patient’s illness.
This is likely to yield safer more effective
treatments that can reliably prevent pro-
gression to ESKD. Close interaction with
federal agencies, biotechnology companies,
and the Food and Drug Administration
will be needed to translate this hope for
improvement into clinical reality.
In addition, to progress in the treat-
ment of kidney disease, there is growing
appreciation of the importance of pre-
vention. This is underscored by the ris-
ing prevalence of CKD and high economic
costs of treating the condition. Moreover,
the problem is exaggerated in underdevel-
oped countries, where the lack of resources
makes the burden of CKD especially heavy.
A number of modifiable risk factors for
CKD have been identified including non-
traditional factors such as obesity, inflam-
mation, and serum phosphate concentra-
tion (11). These factors are often present
early in the disease course during young
adulthood and can adversely impact on
long-term outcomes (12). Thus, improved
screening programs are being developed
to enhance disease detection in high-risk
populations and enable implementation
of prevention strategies before irreversible
injury ensues. Moreover, educational pro-
grams to increase awareness of effective
strategies to prevent CKD are needed, and
they should target all healthcare profes-
sionals including physicians, nurses, dieti-
cians, and social workers. Much progress
has been achieved in promoting these goals
through international nephrology associa-
tions and patient advocacy groups.
THE BIOMARKER DILEMMA
At present, the diagnosis of kidney disease
is almost entirely based on the evaluation
of renal biopsy. This invasive procedure –
granted that it is rather safe – is inconve-
nient, takes time, and often fails to predict
the course of the disease reliably. More
recent advances in genetics and molecu-
lar biology are paving the way for a non-
invasive diagnosis and improved prognos-
tication. The discoveries of APOL1 in renal
disease risk of African-Americans (13) or
the existence of PLA2R antibodies in the
diagnosis of Membranous Nephropathy
(14) are among the recent highlights in
our discipline. While we all embrace the
discovery of such new markers, we must
begin at a more rapid pace to integrate the
associated tests into clinical trial design and
also patient care. While this seems feasible,
these tests are not yet uniformly available,
and associated costs may become out of
hand, hampering the building up of the
momentum necessary to turn the flywheel
for a new biomarker-driven diagnosis and
prognosis for nephrology patients.
THE NECESSITY OF BASIC SCIENTISTS
IN THE CLINICAL SETTING
Impressive advances in basic science
research have been made over the last 10–
20 years that have improved our under-
standing of the pathogenesis of kidney dis-
eases and that point the way to potential
new therapies in the future. For exam-
ple, preclinical studies suggest that renal
injury may be reversible with implementa-
tion of treatment with angiotensin convert-
ing enzyme inhibitors or endothelin antag-
onists (15). Kidney-derived mesenchymal
stem cells may represent a new approach to
the treatment of acute kidney injury and
CKD (16). Finally, discoveries about the
role of the podocyte in the development of
glomerular barrier dysfunction have been
striking. These include identification of
mutations in podocyte proteins that cause
focal segmental glomerulosclerosis and the
role of growth factors and circulating mol-
ecules in modulating podocyte integrity
(17). These findings may pave the way
to improved therapy of proteinuria and
nephrotic syndrome.
The speed at which the field of nephrol-
ogy will move forward with the develop-
ment of novel therapeutics will depend
heavily on the critical number of basic sci-
entists deciphering the molecular mech-
anisms underlying the diverse etiologies
of CKD. Although major funding agen-
cies for research in the US such as the
NIH are trying in a well-intentioned way
to create connections between basic science
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and clinical research by urging basic sci-
entists to explain how their research will
ultimately impact human health, the real-
ity is that such connections simply can-
not be forced. Based on our cumulative
experience, we suggest that the most pro-
ductive connections between basic scien-
tists and clinicians tend to form when a
wealth of basic knowledge of the cellu-
lar and molecular processes acquired by
basic scientists complement the wealth of
knowledge of human physiology acquired
by full-time physicians who treat kidney
patients on a daily basis. In other words,
a mutual interest must exist between the
two parties for them to successfully work
together.
One might wonder why basic scien-
tists would not be highly interested in
working with physicians and vice versa.
From the perspective of basic scientists,
it is not always apparent that the genes,
proteins, or pathways that they are study-
ing might have any relevance to a specific
disease (or any diseases, for that matter).
They may not even be necessarily dri-
ven to understand the mechanisms that
underlie a disease, as they believe, and
we agree that deciphering the secrets of
nature should be sufficiently beneficial for
humanity regardless of whether or not
these discoveries ultimately lead to novel
therapeutics. At the end of the day, not
everything in research must be driven by
the need to develop novel therapeutics or
diagnostics.
From the point of view of the clini-
cians, their lack of familiarity with ever-
changing basic science knowledge and con-
cepts might prevent them from asking per-
tinent questions or from identifying sci-
entists with relevant knowledge. Even if
clinicians find the time in their already
busy schedules to ponder the molecu-
lar mechanisms driving the diseases they
encounter, they may still not be able to dis-
cern from the etiology of the CKD which
pathways or molecules need to be stud-
ied. This problem is compounded by the
fact that basic scientists and full-time clini-
cians often work in separate environments
and rarely interact with one another. Even
at teaching hospitals, clinicians tradition-
ally reside within hospitals while scientists
within their research laboratories. While
clearly there is no single simple solution
for this problem of workspace separation,
there are a few things that could stim-
ulate the formation of scientist–clinician
collaborations.
Clinicians could reach out and approach
scientists in their environment by offer-
ing collaborations – which, in practice,
means providing human samples. Most sci-
entists will at least try to listen and deter-
mine what can be done with those samples,
with some scientists even coming up with
very specific and creative ideas. Basic sci-
entists, on the other hand, could attend
meetings organized by and for clinicians.
Listening to current clinical trials or con-
troversies in the nephrology field would
make it more obvious, where in a clinical
setting, a scientist’s knowledge and under-
standing could best be utilized. Inviting
more basic scientists to speak at such meet-
ings would also prove productive for both
sides. On a smaller scale, the same could
be done more frequently at teaching hospi-
tals or undergraduate universities. As edi-
tors of the Nephrology section of Frontiers
in Medicine, we will try to do our part by
creating a forum in which clinicians and
basic scientists can be interactive in a col-
legial and collaborative manner. We hope
to do this by enlisting a significant num-
ber of basic scientists to serve as reviewers
and also encouraging them to submit their
latest findings to the journal. We invite
clinicians to do likewise in order to facil-
itate an open and dynamic intermix of
basic scientists and clinicians and foster an
exciting dialog. The journal will be fully
committed to a fair and highly qualified
review of all submitted research reports.
In order to ensure a comprehensive assess-
ment by reviewers who have competency
in the topic under consideration, priority
will be given to clinical scientists for the
assessment of clinical studies while basic
scientists will take the lead in the evaluation
of preclinical reports. However, input from
both sides of the investigative spectrum
will be enlisted for all submissions in order
to give each manuscript an open hearing
and to ensure highest quality standards and
utmost rigor.
THE FUTURE BEGINS NOW
Technology and consumer industry oper-
ate according to the principle of instant
gratification. Under those standards, the
world of medicine appears to be a clear out-
lier. The path from a promising discovery
in the laboratory to an effective treatment
often takes a decade or more. It may often
be abruptly halted close to the goal because
of new safety concerns or unanticipated
adverse effects.
But through this process of trial and
error, progress and setbacks, and finally
sustained progress, insights are steadily
growing. Advances that are changing the
course of nephrology are beginning to
be transparent to all who are involved in
nephrology research and patient care. In
order to maintain the accelerating pace
of nephrology developments and to build
momentum,we have to continue to seek for
new ways to assess normal and pathological
kidney function.
CHANGE IS DIFFICULT
Nephrology is a discipline that shares fea-
tures with another prominent discipline,
namely neurology. Both are characterized
by a high fund of knowledge amongst
the specialists but a difficulty to translate
knowledge into clinical actions due to the
lack of new medications or other technol-
ogy of precision medicine. This is a huge
problem that ultimately feeds back to our
trainees who consider other career paths
that may appear more exciting. Oncology
has undoubtedly attracted many trainees
because exciting new drugs are being devel-
oped in this area. What does that mean for
our scientists or scientists who study the
kidney and its related systems? We must
embrace translational medicine and we
must allow for molecules and novel drug
targets to be further evaluated by indus-
try even in the presence of some knowl-
edge gaps. This is clearly a shortcoming in
our field that only we can overcome – let
us be brave.
REFERENCES
1. Ritz E, Wiecek A. The kidney in the bible. Dtsch
Med Wochenschr (2006) 131(51–52):2916–9. doi:
10.1055/s-2006-957222
2. Merrill JP, Murray JE, Harrison JH, Guild WR.
Landmark article Jan 28, 1956: successful homo-
transplantation of the human kidney between
identical twins. By John P. Merrill, Joseph E. Mur-
ray, J. Hartwell Harrison, and Warren R. Guild.
JAMA (1984) 251(19):2566–71. doi:10.1001/jama.
251.19.2566
3. Parker MG, Ibrahim T, Shaffer R, Rosner MH,
Molitoris BA. The future nephrology workforce:
will there be one? Clin J Am Soc Nephrol (2011)
6(6):1501–6. doi:10.2215/CJN.01290211
4. Parker MG, Pivert KA, Ibrahim T, Molitoris BA.
Recruiting the next generation of nephrologists.
Frontiers in Medicine | Nephrology September 2014 | Volume 1 | Article 28 | 4
Trachtman et al. The grand challenge of nephrology
Adv Chronic Kidney Dis (2013) 20(4):326–35. doi:
10.1053/j.ackd.2013.03.004
5. Al-Awqati Q. Basic research in nephrology: are we
in decline? JAmSocNephrol (2012) 23(10):1611–6.
doi:10.1681/ASN.2012060553
6. Samuels JA, Molony DA. Randomized con-
trolled trials in nephrology: state of the evidence
and critiquing the evidence. Adv Chronic Kidney
Dis (2012) 19(1):40–6. doi:10.1053/j.ackd.2012.
01.009
7. Bryan L, Ibrahim T, Zent R, Fischer MJ. The kid-
ney research predicament. J AmSocNephrol (2014)
25(5):898–903. doi:10.1681/ASN.2013121313
8. Strippoli GF, Craig JC, Schena FP. The num-
ber, quality, and coverage of randomized
controlled trials in nephrology. J Am Soc
Nephrol (2004) 15(2):411–9. doi:10.1097/01.ASN.
0000100125.21491.46
9. Inrig JK, Califf RM, Tasneem A, Vegunta RK,
Molina C, Stanifer JW, et al. The landscape of
clinical trials in nephrology: a systematic review
of Clinicaltrials.gov. Am J Kidney Dis (2014)
63(5):771–80. doi:10.1053/j.ajkd.2013.10.043
10. Gadegbeku CA, Gipson DS, Holzman LB, Ojo
AO, Song PX, Barisoni L, et al. Design of the
Nephrotic Syndrome Study Network (NEPTUNE)
to evaluate primary glomerular nephropathy by
a multidisciplinary approach. Kidney Int (2013)
83(4):749–56. doi:10.1038/ki.2012.428
11. Wickman C, Kramer H. Obesity and kidney
disease: potential mechanisms. Semin Nephrol
(2013) 33(1):14–22. doi:10.1016/j.semnephrol.
2012.12.006
12. McMahon GM, Preis SR, Hwang SJ, Fox CS. Mid-
adulthood risk factor profiles for CKD. J Am Soc
Nephrol (2014). doi:10.1681/ASN.2013070750
13. Genovese G, Friedman DJ, Ross MD, Lecordier
L, Uzureau P, Freedman BI, et al. Association
of trypanolytic ApoL1 variants with kidney
disease in African Americans. Science (2010)
329(5993):841–5. doi:10.1126/science.1193032
14. Beck LH Jr, Bonegio RG, Lambeau G, Beck
DM, Powell DW, Cummins TD, et al. M-type
phospholipase A2 receptor as target antigen
in idiopathic membranous nephropathy. N
Engl J Med (2009) 361(1):11–21. doi:10.1056/
NEJMoa0810457
15. Barton M. Reversal of proteinuric renal disease
and the emerging role of endothelin. Nat Clin
Pract Nephrol (2008) 4(9):490–501. doi:10.1038/
ncpneph0891
16. Rosenberg ME. Cell-based therapies in kidney dis-
ease. Kidney Int Suppl (2013) 3(4):364–7. doi:10.
1038/kisup.2013.78
17. Reiser J, Sever S. Podocyte biology and patho-
genesis of kidney disease. Annu Rev Med
(2013) 64:357–66. doi:10.1146/annurev-med-
050311-163340
Conflict of Interest Statement: The authors declare
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 07 August 2014; accepted: 22 August 2014;
published online: 18 September 2014.
Citation: Trachtman H, Benzing T, Sever S, Harris RC
and Reiser J (2014) The grand challenge of nephrology.
Front. Med. 1:28. doi: 10.3389/fmed.2014.00028
This article was submitted to Nephrology, a section of the
journal Frontiers in Medicine.
Copyright © 2014 Trachtman, Benzing , Sever , Harris
and Reiser . This is an open-access article distributed
under the terms of the Creative Commons Attribution
License (CC BY). The use, distribution or reproduc-
tion in other forums is permitted, provided the original
author(s) or licensor are credited and that the original
publication in this journal is cited, in accordance with
accepted academic practice.Nouse, distribution or repro-
duction is permitted which does not comply with these
terms.
www.frontiersin.org September 2014 | Volume 1 | Article 28 | 5
